Union européenne -
français -
EMA (European Medicines Agency)
beyfortus
astrazeneca ab - nirsevimab - des sérums et immunoglobulines, - beyfortus is indicated for the prevention of respiratory syncytial virus (rsv) lower respiratory tract disease in neonates and infants during their first rsv season. beyfortus should be used in accordance with official recommendations.
Canada -
français -
Health Canada
beyfortus solution
astrazeneca canada inc - nirsévimab - solution - 50mg - nirsévimab 50mg
Canada -
français -
Health Canada
beyfortus solution
astrazeneca canada inc - nirsévimab - solution - 100mg - nirsévimab 100mg
Suisse -
français -
Swissmedic (Swiss Agency for Therapeutic Products)
beyfortus 50 mg/0.5 ml solution injectable en seringue préremplie
sanofi-aventis (suisse) sa - nirsevimabum - solution injectable en seringue préremplie - nirsevimabum 50 mg, histidinum, histidini hydrochloridum monohydricum, arginini hydrochloridum, saccharum, polysorbatum 80, aqua ad iniectabile ad solutionem pro 0.5 ml. - prévention des maladies à rsv - biotechnologika
Suisse -
français -
Swissmedic (Swiss Agency for Therapeutic Products)
beyfortus 100 mg/1 ml solution injectable en seringue préremplie
sanofi-aventis (suisse) sa - nirsevimabum - solution injectable en seringue préremplie - nirsevimabum 100 mg, histidinum, histidini hydrochloridum monohydricum, arginini hydrochloridum, saccharum, polysorbatum 80, aqua ad iniectabile ad solutionem pro 1 ml. - prévention des maladies à rsv - biotechnologika
Canada -
français -
Health Canada
casirivimab et imdevimab solution
hoffmann-la roche limited - casirivimab; imdévimab - solution - 1332mg; 1332mg - casirivimab 1332mg; imdévimab 1332mg - monoclonal antibodies
Canada -
français -
Health Canada
casirivimab et imdevimab solution
hoffmann-la roche limited - casirivimab; imdévimab - solution - 300mg; 300mg - casirivimab 300mg; imdévimab 300mg - monoclonal antibodies
Union européenne -
français -
EMA (European Medicines Agency)
evusheld
astrazeneca ab - tixagevimab, cilgavimab - covid-19 virus infection - prevention of covid-19.
Canada -
français -
Health Canada
evusheld solution
astrazeneca canada inc - tixagévimab; cilgavimab - solution - 150mg; 150mg - tixagévimab 150mg; cilgavimab 150mg
Suisse -
français -
Swissmedic (Swiss Agency for Therapeutic Products)
evusheld solution injectable
astrazeneca ag - tixagevimabum, cilgavimabum - solution injectable - a): tixagevimabum 150 mg, histidinum, histidini hydrochloridum monohydricum, saccharum, polysorbatum 80, aqua ad iniectabile, ad solutionem pro 1.5 ml. b): cilgavimabum 150 mg, histidinum, histidini hydrochloridum monohydricum, saccharum, polysorbatum 80, aqua ad iniectabile, ad solutionem pro 1.5 ml. - behandlung und prä-expositionsprophylaxe von covid-19 - biotechnologika